Lenvat 4 (Lenvatinib) 4 mg
5277₴
6156₴
-14%
Lenvat 4 mg is a premium generic tyrosine kinase inhibitor manufactured by Natco Pharma (India). Active ingredient: Lenvatinib (4 mg).
Why Natco?
Natco is renowned for producing high-purity oncology drugs that match the efficacy of the originator brand Lenvima. Lenvat works by inhibiting multiple receptors (VEGFR, FGFR, RET) to starve the tumor of blood supply.
Usage of 4 mg Dose:
This strength is essential for dose titration, management of toxicity (dose reduction), and specifically for Liver Cancer patients with low body weight (< 60 kg).
Approved for:
- Hepatocellular Carcinoma (HCC): Unresectable liver cancer (First-line).
- Differentiated Thyroid Cancer (DTC): Progressive, radioiodine-refractory.
- Renal Cell Carcinoma (RCC): Advanced kidney cancer (with Everolimus).
Strength: 4 mg per capsule.
Common Dosing Scenarios:
- Liver Cancer (< 60 kg body weight): 8 mg (2 capsules) once daily.
- Liver Cancer (≥ 60 kg body weight): 12 mg (3 capsules) once daily.
- Dose Reduction: If toxicity occurs at high doses (e.g., 24 mg), the doctor may reduce the dose to 20 mg, 14 mg, or 10 mg using combinations of capsules.
⚠️ Instruction: Swallow whole with water. Do not open or crush.
- Uncontrolled Hypertension.
- Severe hepatic impairment.
- Pregnancy and breastfeeding.
- History of gastrointestinal fistula.
Adverse events are common:
- Hypertension: Monitor blood pressure daily.
- Proteinuria: Regular urinalysis is required.
- Hand-Foot Syndrome: Redness/pain on palms and soles.
- Fatigue and Diarrhea.
100% original product
Delivery across Ukraine
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!